Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

122.88
+1.891.56%
Post-market: 122.880.00000.00%19:30 EDT
Volume:27.57K
Turnover:3.37M
Market Cap:554.19M
PE:6.37
High:123.25
Open:120.60
Low:120.60
Close:120.99
52wk High:131.68
52wk Low:92.10
Shares:4.51M
Float Shares:4.51M
Volume Ratio:0.76
T/O Rate:0.61%
Dividend:1.13
Dividend Rate:0.92%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.66
PE(LYR):5.65

Loading ...

Boston Scientific Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
4 hours ago

Amgen Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
5 hours ago

Abbott Laboratories Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
5 hours ago

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
5 hours ago

U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie

Reuters
·
7 hours ago

Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says

MT Newswires Live
·
Yesterday

UBS Lifts AbbVie Target as Focus Expands Beyond Immunology Drugs

Reuters
·
Yesterday

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Yesterday

Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

TIPRANKS
·
Yesterday

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Abbvie Inc. : UBS Raises Target Price to $275 from $260

THOMSON REUTERS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Yesterday

MedTech Growth Concerns Likely to Overshadow Q3 Results, Leerink Says

Reuters
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Yesterday

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Yesterday

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Yesterday

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Yesterday

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday